Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Boundless Bio Inc. (BOLD) Stock Price & Analysis

54 Followers

BOLD Stock Chart & Stats

$2.50$0.04(1.63%)
At close: 4:00 PM EST
$2.5$2.75$3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$2.39 - $2.54
52-Week Range
$0.96 - $3.16
Previous Close
$2.46
Volume
N/A
Average Volume (3M)
136.81K
Market Cap
$58.08M
Enterprise Value
-$5.50M
Total Cash (Recent Filing)
$62.89M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.02
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

The absence of TTM debt and presence of positive equity reduce near-term solvency pressure and preserve flexibility for research spending. This gives Boundless Bio a stronger financial base than a similarly unprofitable biotech carrying substantial current leverage, although it does not eliminate future funding needs.

Differentiated EcDNA Focus

A focused approach to ecDNA gives Boundless Bio a distinct scientific positioning within oncology and targets mechanisms associated with difficult-to-treat tumors. If its candidates validate clinically, this specialization could support differentiated products and durable relevance in precision cancer therapy.

Merger Financing Flexibility

The amended merger terms provide clearer treatment of financing, employee awards, and ownership limits while lowering the voting threshold for increasing authorized shares. These structural changes may make the transaction easier to approve and give the combined company greater capital-structure flexibility.

Bears Say

Pre-Revenue Business

With no reported revenue, Boundless Bio has not yet demonstrated commercial demand or an operating cash inflow from products. The company must continue funding development before it can establish recurring sales, making future financial performance highly dependent on clinical progress and eventual commercialization.

Persistent Cash Burn

Sustained operating and free-cash-flow deficits consume the resources needed to advance the pipeline and imply continued reliance on external financing. The TTM burn rate is material relative to the company’s capital base, increasing dilution or funding pressure if development spending remains elevated.

Capitalization Volatility

Large swings in debt and equity indicate that Boundless Bio’s capitalization has depended materially on financing and recapitalization activity. Although current debt is absent, this history and the step-down in TTM equity suggest that ongoing losses can erode financial capacity and require additional capital.

Boundless Bio Inc. News

BOLD FAQ

What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $0.96 and its highest was $3.16 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Boundless Bio Inc.’s market cap is $58.08M.
When is Boundless Bio Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Boundless Bio Inc.’s earnings last quarter?
Boundless Bio Inc. released its earnings results on Nov 05, 2026. The company reported -$0.235 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.005.
Is Boundless Bio Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 23,611,406 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Boundless Bio Inc. reported an EPS of -$0.235 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went up 0.417%.
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Hedge funds hold Boundless Bio Inc. shares: the largest hedge-fund position in Boundless Bio Inc. is 71,884,265 shares, and hedge funds increased their holdings by 17.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology